A Randomized, Double-blind, Placebo-controlled Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the FXR-agonist EYP001a in Chronically HBV Infected Subjects

Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the FXR-agonist EYP001a in Chronically HBV Infected Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs EYP 001 (Primary) ; Entecavir; Peginterferon alfa-2a
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Sponsors ENYO Pharma
  • Most Recent Events

    • 20 Oct 2017 Status changed from not yet recruiting to recruiting.
    • 28 Dec 2016 New trial record
    • 19 Dec 2016 According to a Poxel media release, this trial is expected to be initiated in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top